Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient

J Gastrointest Cancer. 2012 Sep:43 Suppl 1:S89-92. doi: 10.1007/s12029-011-9328-3.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / prevention & control*
  • Dose-Response Relationship, Drug
  • Humans
  • Liver Neoplasms / complications
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives*
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use*
  • Prognosis
  • Sorafenib

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Niacinamide
  • Sorafenib